# A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity

> **NCT07310563** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 59 (actual)

## Conditions studied

- Overweight
- Obesity

## Interventions

- **DRUG:** AMG 133
- **DRUG:** Ondansetron

## Key facts

- **NCT ID:** NCT07310563
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-10
- **Primary completion:** 2025-05-09
- **Final completion:** 2025-05-09
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07310563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07310563, "A Trial to Evaluate Interactions Between Antiemetic Medication and AMG 133 in Participants Living With Overweight or Obesity". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07310563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*